Back to Journals » Journal of Pain Research » Volume 13

Reducing Episodic Cluster Headaches: Focus on Galcanezumab

Authors Pellesi L, De Icco R, Al-Karagholi MA, Ashina M

Received 21 April 2020

Accepted for publication 8 June 2020

Published 2 July 2020 Volume 2020:13 Pages 1591—1599

DOI https://doi.org/10.2147/JPR.S222604

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr E Alfonso Romero-Sandoval


Lanfranco Pellesi,1 Roberto De Icco,2,3 Mohammad Al-Mahdi Al-Karagholi,1 Messoud Ashina1,4

1Danish Headache Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Headache Science Center, IRCCS Mondino Foundation, Pavia, Italy; 3Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; 4Danish Headache Knowledge Center, Rigshospitalet Glostrup, Glostrup, Denmark

Correspondence: Lanfranco Pellesi
Danish Headache Center, Faculty of Health and Medical Sciences, University of Copenhagen, Vagtelvej 61, Copenhagen 2000, Denmark
Tel +393409383056
Email lanfranco.pellesi@gmail.com

Abstract: The involvement of calcitonin gene-related peptide in migraine and cluster headache has led to the recent development of new therapies. Galcanezumab, a novel monoclonal antibody targeting the calcitonin gene-related peptide, is approved for the migraine prevention and has recently been tested for the prevention of cluster headache. Two clinical trials have been conducted to investigate the efficacy and safety of galcanezumab in episodic cluster headache and chronic cluster headache. While efficacy endpoints were not met in the chronic subtype, galcanezumab reduced the weekly frequency of attacks in patients with episodic cluster headaches. In both studies, the antibody was well tolerated. This review summarizes and critically reviews the available data regarding the rationale behind targeting the calcitonin gene-related peptide with galcanezumab for the prevention of cluster headache.

Keywords: cluster headache, calcitonin gene-related peptide, CGRP, antibody, LY2951742

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]